Colorectal cancer vaccine: Targeted Diagnostics & Therapeutics

Drug Profile

Colorectal cancer vaccine: Targeted Diagnostics & Therapeutics

Latest Information Update: 07 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Thomas Jefferson University
  • Developer Targeted Diagnostics and Therapeutics; Thomas Jefferson University
  • Class Cancer vaccines
  • Mechanism of Action Guanylate cyclase C modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer

Most Recent Events

  • 22 Nov 2016 Viral Gene plans to apply to the US FDA for Orphan Drug Designation for the cancer vaccine
  • 22 Nov 2016 Targeted Diagnostics & Therapeutics and Viral gene plan a clinical trial for Colorectal cancer in South Korea
  • 22 Nov 2016 Targeted Diagnostics & Therapeutics and Viral gene plan a phase II trial for Colorectal cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top